PubMed HealthSearch

PubMed · 6794319

Delayed decrease in serum ferritin in polytransfused children with thalassemia major after continuous subcutaneous infusions of desferrioxamine.

Abstract

A longitudinal study has been conducted on serum ferritin concentrations in children with thalassemia major treated with desferrioxamine (DFO), both intramuscularly and by continuous subcutaneous infusion, in order to evaluate the time interval after which iron chelation becomes effective. In a first group of 19 children, treated intramuscularly with DFO at a dose of 20 mg/kg for 20 days a month, ferritin levels were followed for 739 days and a progressive increase with a significant linear correlation with time was seen. The daily increase was calculated to be 8.53 +/- 1.95 ng/ml. In the second group of 12 children treated with DFO by continuous subcutaneous infusion (greater than or equal to 20 mg/kg/day for 6 days a week), the increase in ferritin was markedly lower, the mean daily value being 4.77 +/- 3.30 ng/ml. Only after the first 360 days of treatment did the serum ferritin decrease, by 1.95 +/- 3.32 ng/ml/day, in spite of a mean daily iron contribution from blood transfusions of 7.09 +/- 2.69 mg/day. These changes in serum ferritin led us to conclude that one can only expect to obtain a decrease in the body's iron overload after more than a year of treatment with subcutaneous DFO.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F Schettini, A Mautone, L Cavallo, M Altomare, O Montagna, L Dell'Edera. 1981. Delayed decrease in serum ferritin in polytransfused children with thalassemia major after continuous subcutaneous infusions of desferrioxamine.. https://doi.org/10.1159/000207104

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Autologous blood transfusion in Auckland.

AIMS: To review autologous blood collection and transfusion practice in Auckland over the last five years. METHOD: Records of autologous blood collections were obtained from blood collection centre records and results of transfusions on patients from hospital notes. RESULTS: One hundred and sixty-four units of blood were collected from 77 patients. Seventy-five percent of the units collected were transfused. Most autologous blood was transfused to private hospital patients. Only 8% of patients required homologous blood. CONCLUSIONS: There has been a slow increase of autologous blood collection and transfusion in the Auckland area, as well as in the rest of New Zealand. The present risks of homologous transfusion, particularly since the introduction of hepatitis C testing, appear very low. A further expansion of the present autologous blood programme would entail increased expenditure and it is suggested that a critical cost benefit analysis would be useful before the programme is expanded.

Blood Transfusion